Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2321138A (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

Most Recent Events

18 Mar 2013 Primary endpoint added as reported by ClinicalTrials.gov.
22 Nov 2012 Results were presented at IDWeek in October 2012, according to a GlaxoSmithKline media release.
22 Nov 2012 Primary endpoint 'Haemagglutin-inhibition-antibody-levels' in children aged 3-17 years has been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com